Ephedrine Sulfate — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	IV	0.02-0.1 mg/kg	As needed (bolus)	Duration: During anesthesia Notes: Titrate to effect; may be repeated every 5-10 minutes.
Dog	PO	2-5 mg/kg	q8-12h	Duration: For urinary incontinence (off-label) Notes: Use with caution in patients with cardiac disease.
Cat	IV	0.02-0.1 mg/kg	As needed (bolus)	Duration: During anesthesia Notes: Titrate to effect; may be repeated every 5-10 minutes.
Horse	IV	0.02-0.1 mg/kg	As needed (bolus)	Duration: During anesthesia Notes: Titrate to effect; may be repeated every 5-10 minutes.
Cattle	IV	0.02-0.1 mg/kg	As needed (bolus)	Duration: During anesthesia Notes: Titrate to effect; may be repeated every 5-10 minutes.
Small Ruminants	IV	0.02-0.1 mg/kg	As needed (bolus)	Duration: During anesthesia Notes: Titrate to effect; may be repeated every 5-10 minutes.
Rabbit	IV	0.02-0.1 mg/kg	As needed (bolus)	Duration: During anesthesia Notes: Titrate to effect; may be repeated every 5-10 minutes.

Clinical Indications & Species Uses

General Indications

Treatment of hypotension associated with anesthesia
Temporary management of bradycardia
Bronchodilation (off-label)

Dog (Canine)

Hypotension during anesthesia
Bradycardia (as a temporary measure)
Narcolepsy (off-label)
Urinary incontinence (off-label, due to alpha effects)

Cat (Feline)

Hypotension during anesthesia
Bradycardia (as a temporary measure)

Horse (Equine)

Hypotension during anesthesia
Bradycardia
Bronchoconstriction (off-label)

Cattle (Bovine)

Hypotension during anesthesia
Bradycardia

Small Ruminants (Sheep / Goat)

Hypotension during anesthesia
Bradycardia

Rabbit & Small Mammals

Hypotension during anesthesia
Bradycardia

Exotic & Other Species

Hypotension during anesthesia in some exotic species (off-label)

Pharmacology & Mechanism of Action

Drug Class: Sympathomimetic | Pharmacological Group: Alpha and beta adrenergic agonist

Mechanism of Action: Ephedrine sulfate is a sympathomimetic amine that acts both directly and indirectly on adrenergic receptors. It stimulates alpha and beta receptors directly, and also promotes the release of norepinephrine from presynaptic nerve terminals. The alpha-adrenergic effects cause vasoconstriction and increased peripheral vascular resistance, leading to increased blood pressure. Beta-adrenergic effects result in positive inotropy and chronotropy, increasing cardiac output. Additionally, it causes bronchodilation and central nervous system stimulation.

Pharmacodynamics: Ephedrine produces a rise in systolic and diastolic blood pressure, with a reflex bradycardia that may be overcome by its direct chronotropic effect. It increases cardiac output, peripheral resistance, and venous return. It also relaxes bronchial smooth muscle and may increase metabolic rate. Central effects include stimulation of the respiratory center and increased alertness. Tolerance to its pressor effects can develop with repeated administration.

⚡ Pharmacokinetics Summary

Absorption: Ephedrine is well absorbed after oral, intramuscular, and subcutaneous administration. Oral bioavailability is approximately 85% in humans, but may vary in animals. Onset of action after oral administration is within 15-60 minutes, while parenteral routes produce effects within minutes.

Distribution: Ephedrine is widely distributed throughout the body, including the central nervous system. It crosses the blood-brain barrier and placenta. It has a volume of distribution of about 2-3 L/kg in humans.

Metabolism: Ephedrine undergoes minimal hepatic metabolism, primarily by oxidative deamination and demethylation. It is largely excreted unchanged in the urine.

Excretion: Ephedrine is primarily excreted unchanged in the urine, with renal excretion dependent on urinary pH. Acidic urine increases elimination, while alkaline urine decreases it. The elimination half-life is approximately 3-6 hours in humans, but may be shorter in some species.

Half-Life: Dogs: 1-2 hours; Cats: 2-4 hours; Horses: 1-2 hours (estimated)

Bioavailability: Oral: ~85% in humans; variable in animals; IM/SC: complete

Protein Binding: Low, approximately 5-10%

Available Formulations & Strengths

Injectable Solution 50 mg/mL (IV, IM, SC)

Oral Tablet 25 mg, 50 mg (PO)

Oral Capsule 25 mg, 50 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to ephedrine or other sympathomimetics
Severe hypertension
Tachyarrhythmias
Concurrent use of MAO inhibitors
Severe coronary artery disease
Hyperthyroidism (relative)
Angle-closure glaucoma

Warnings & Clinical Precautions:

Use with caution in patients with cardiovascular disease, hypertension, or arrhythmias.
May cause CNS stimulation; use with caution in animals with seizure disorders.
Tolerance may develop with prolonged use.
In food animals, observe withdrawal times.
Use with caution in patients with prostatic hypertrophy (may worsen urinary retention).
Avoid in patients with pheochromocytoma.

Adverse Effects & Reactions

Common:

Tachycardia
Hypertension
Restlessness
Tremors
Anorexia
Vomiting

Serious / Severe:

Arrhythmias
Myocardial ischemia
Cerebral hemorrhage
Pulmonary edema
Seizures

Rare:

Hypersensitivity reactions
Necrosis at injection site (with extravasation)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
MAO inhibitors	Severe hypertensive crisis due to increased norepinephrine release	High
Halogenated anesthetics (e.g., halothane)	Increased risk of ventricular arrhythmias	High
Beta-blockers (e.g., propranolol)	Unopposed alpha-adrenergic effects may cause severe hypertension	High
Digoxin	Increased risk of arrhythmias	Moderate
Diuretics	Hypokalemia may increase risk of arrhythmias	Moderate
Theophylline	Additive CNS stimulation and cardiovascular effects	Moderate
Oxytocin	Additive pressor effects	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Severe hypertension
Tachycardia
Arrhythmias
Seizures
Cerebral hemorrhage
Hyperthermia
Respiratory depression

Emergency Treatment Protocol: Discontinue the drug immediately. Provide supportive care: monitor vital signs, ECG, and blood pressure. For severe hypertension, use a short-acting alpha-blocker (e.g., phentolamine) or a vasodilator (e.g., nitroprusside). For tachyarrhythmias, consider beta-blockers (e.g., propranolol) with caution. Control seizures with diazepam or barbiturates. Cool the patient if hyperthermic. Administer fluids to maintain perfusion but avoid fluid overload.

Food Animal Withdrawal Times

🥩 Meat: 14 days🥛 Milk: 3 days

Withdrawal times are estimates; consult label or regulatory authority. Ephedrine is not approved for food animals in many countries; extra-label use requires extended withdrawal periods.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25°C, excursions permitted to 15-30°C).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light. Keep container tightly closed. Do not freeze.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Ephedrine sulfate is not FDA-approved for veterinary use in the US, but it is available as a human generic drug and may be used legally in animals under the Animal Medicinal Drug Use Clarification Act (AMDUCA) with a valid veterinarian-client-patient relationship.

Extra-Label (Off-Label) Use: In the US, extra-label use of ephedrine in food animals is prohibited by the FDA due to lack of established withdrawal times and potential for residues. In non-food animals, extra-label use is permitted under AMDUCA with appropriate veterinary oversight.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Ephedrine sulfate is a valuable agent for the treatment of hypotension during anesthesia, particularly in dogs, cats, and horses. It is often used as a first-line vasopressor due to its combined alpha and beta effects. However, its use requires careful monitoring of heart rate and blood pressure, as it can cause tachyarrhythmias and excessive hypertension. In small animal practice, it is also used off-label for urinary incontinence due to its alpha-adrenergic effects on the urethral sphincter. Tolerance can develop with repeated dosing, so it is not ideal for long-term management. In food animals, its use is highly restricted due to regulatory concerns. Always consider the individual patient's cardiovascular status and potential drug interactions before administration.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)